GSE95771 AG221 and Ruxolitinib Treatment Effects on LSKs in IDH2-R140Q JAK2-V617F Transplant Recipients

Contributors : Anna S McKenney ; Barbara Spitzer ; Ross L LevineSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTransplant recipients of IDH2-R140Q JAK2-V617F expressing bone marrow were treated with AG221 and ruxolitinib monotherapy, combined therapy, or vehicle. LSKs were sorted from terminal samples and sequenced with three WT controls.

http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95771

Source: GEO: Gene Expression Omnibus - February 22, 2018 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

More News: Genetics | Transplants